MRK · 10-Q · 2026Q3 · Full report
Keytruda SC Litigation
Merck & Co., Inc. · 2026-11-04 · Importance 42 · Surprise 48 · In source text
Preliminary injunctions prohibit continued Keytruda SC sales in Denmark and Italy and prevent launches in Germany, The Netherlands, Belgium, Ireland and France. Commercial availability in EU countries also depends on reimbursement procedures and the outcome of litigation with Halozyme, Inc. The filing does not quantify the financial effect of the injunctions.
Key facts
- Preliminary injunctions prohibit continued Keytruda SC sales in Denmark and Italy and prevent launches in Germany, the Netherlands, Belgium, Ireland and France. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Preliminary injunctions prohibit continued Keytruda SC sales in Denmark and Italy and prevent launches in Germany, the Netherlands,… |